Biology 2013, 2(2), 587-602; doi:10.3390/biology2020587
Antitumor Virotherapy by Attenuated Measles Virus (MV)
1
INSERM, UMR892, Nantes, F-44000, France
2
CNRS, UMR6299, Nantes, F-44000, France
3
Université de Nantes, Nantes, F-44000, France
4
CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France
*
Author to whom correspondence should be addressed.
Received: 4 February 2013 / Revised: 28 February 2013 / Accepted: 5 March 2013 / Published: 28 March 2013
(This article belongs to the Special Issue RNA Viruses and Cancer)
View Full-Text
|
Download PDF [174 KB, uploaded 28 March 2013]
Abstract
Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response. View Full-TextKeywords:
antitumor virotherapy; measles virus vaccine; dendritic cells; tumor antigen; clinical trial; vaccine
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Guillerme, J.-B.; Gregoire, M.; Tangy, F.; Fonteneau, J.-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013, 2, 587-602.